profit from every $100 of sales.
$0$100
Tactile Systems Technology
$27.13+1.92% today
+8.1% in 1 year
1-year low $21.711-year high $33.05
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $31.84 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Tactile Systems Technology sold, what it kept, and what it did with the cash.
Sales went from $247 million in 2022 to $330 million in 2025, with $19.1 million of profit last year.
SalesProfit
Tactile Systems Technology handed back 66% of the cash it generated last year.
Buybacks $27M
Free cash flow 2025$40M
Bought back its own shares$27M
Paid as dividends–
Cash vs. debt$83M vs. $16M
Tactile Systems Technology vs. similar companies
Tactile Systems Technology grows in the middle of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Tactile Systems Technology | 31.8× · Expensive | ||
 Boston Scientific | 22.6× · Fair price | ||
 Koninklijke Philips | 29.7× · Fair price | ||
 Steris | 31.8× · Expensive | ||
 Zimmer Biomet Holdings | 28.8× · Fair price |
AI analysis
An AI analyst reads Tactile Systems Technology's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 247 | 274 | 293 | 330 | |
| 176 | 195 | 217 | 250 | |
| -13 | 18 | 22 | 29 | |
| 2 | 26 | 32 | 39 | |
| -18 | 29 | 17 | 19 | |
| -0.89 | 1.23 | 0.70 | 0.82 | |
| 71.3% | 71.1% | 74.0% | 75.9% | |
| -5.2% | 6.6% | 7.6% | 8.9% | |
| -7.2% | 10.4% | 5.8% | 5.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 255 | 281 | 298 | 274 |
| Cash | 22 | 61 | 94 | 83 |
| Total debt | 72 | 50 | 45 | 16 |
| Total liabilities | 134 | 88 | 81 | 55 |
| 121 | 194 | 217 | 219 | |
| 20 | 23 | 24 | 23 | |
| -5.2% | 6.4% | 7.7% | 10.9% | |
| -14.7% | 14.7% | 7.8% | 8.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 5 | 36 | 41 | 43 | |
| 2 | 2 | 3 | 3 | |
| 3 | 33 | 38 | 40 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | 4 | 27 | |
| 10 | 8 | 8 | 8 |
Valuation
- 31.8×
- 23.8×
- –
- 2.5×
- 1.8×
- 15.1×
- 13.8×
- 6.6%
- 3.1%
- 0.0%
Profitability
- 75.9%
- 8.9%
- 5.8%
- 11.9%
- 7.9%
- 2.3%
- 9.7%
- 7.5%
- 13.7%
- 2.8%
Growth
- +10.1%
- –
- +6.0%
- –
- +3.8%
Financial health
- -1.5×
- 0.07
- 5.6%
- 71.9×
- 4.24
- 3.78
- 1.26
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 39%of 958
Bottom 48%of 889
Bottom 40%of 601
Bottom 47%of 890
Top 15%of 987
What analysts expect
- Average price target
- $38.75
- Range
- $35.00 – $42.00
- 3 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 4, 2026 | -0.08 | -0.07 | −14.3% |
| Feb 17, 2026 | 0.46 | 0.44 | +4.5% |
| Nov 3, 2025 | 0.36 | 0.16 | +125.0% |
| Aug 4, 2025 | 0.14 | 0.09 | +55.6% |
| May 5, 2025 | -0.13 | -0.07 | −85.7% |
| Feb 18, 2025 | 0.40 | 0.31 | +29.0% |
| Nov 4, 2024 | 0.21 | 0.18 | +16.7% |
| Aug 5, 2024 | 0.18 | 0.12 | +50.0% |
News
Tactile Medical targets $50M-$52M adjusted EBITDA in 2026 while maintaining $360M-$366M revenue outlookSeeking Alpha · Nov 3, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
55No pass
Benjamin Graham
43No pass
Philip Fisher
46No pass
Peter Lynch
58No pass
Joel Greenblatt
28No pass
Charlie Munger
42No pass
Terry Smith
48No pass
Questions about Tactile Systems Technology
Is Tactile Systems Technology a good stock to buy?
A business with weak numbers, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Tactile Systems Technology AI analysis
What does Tactile Systems Technology do?
Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. It is in Medical - Devices.
Does Tactile Systems Technology pay a dividend?
No. Tactile Systems Technology does not pay a dividend at the moment; in 2025 it returned $26.6 million to shareholders by buying back its own shares.
Is Tactile Systems Technology stock halal?
Yes. Tactile Systems Technology passes our halal screen: its business is permitted and its debt is 3% of its market value, under the 30% limit. How we check
How has Tactile Systems Technology stock done over the past year?
Up 8.1% over the past twelve months, to $27.13. It traded between $21.71 and $33.05 and is 17.9% below its high.
Who are Tactile Systems Technology's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with Tactile Systems Technology's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.